Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study

Tiago Torres^{1

2}, Jensen Yeung^{3

4

5

6}, Vimal Prajapati^{7

8

9

10}, Simone Ribero¹¹, Anna Balato¹², Angelo Valerio Marzano^{13

14}, Maria João Cruz^{15

16}, Maria João Paiva Lopes¹⁷, Elizabeth Lazaridou¹⁸, Jose-Manuel Carrascosa¹⁹, José Miguel Alvarenga¹, Pedro Farinha¹⁷, Bruno Duarte¹⁷, Siddhartha Sood²⁰, Brian D Rankin⁷, Michela Ortoncelli¹¹, Stefano Caccavale¹², Silvia Mariel Ferrucci¹³, Gilberto Pires Rosa^{15

16}, Athina Ioanna Daponte¹⁸, Gianmarco Silvi²¹, Ketty Peris^{22

23}, Niccolò Gori^{22

23}, Pedro Herranz¹⁹, Francesca Prignano²¹, Antonio Kolios^{24

25}, Natalia Rompoti²⁶, Spyridon Gkalpakiotis²⁶, Andrea Chiricozzi^{22

23}

Affiliations

¹ Department of Dermatology, Centro Hospitalar Universitário de Santo António Porto, Porto, Portugal.
² Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
³ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁴ Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada.
⁵ Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
⁶ Probity Medical Research, Toronto, Ontario, Canada.
⁷ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
⁸ Dermatology Research Institute, Calgary, Alberta, Canada.
⁹ Skin Health & Wellness Centre, Calgary, Alberta, Canada.
¹⁰ Probity Medical Research, Calgary, Alberta, Canada.
¹¹ Department of Medical Sciences, Dermatology Clinic, University of Turin, Turin, Italy.
¹² Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy.
¹³ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
¹⁴ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
¹⁵ Department of Dermatology, Unidade Local de Saúde de São João, Porto, Portugal.
¹⁶ Faculty of Medicine, University of Porto, Porto, Portugal.
¹⁷ Dermatology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
¹⁸ Department of Dermatology-Venereology, Aristotle University School of Medicine, Thessaloniki, Greece.
¹⁹ Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
²⁰ Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
²¹ Department of Health Sciences Dermatology Section, University of Florence, Florence, Italy.
²² Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
²³ U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
²⁴ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
²⁵ Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland.
²⁶ Department of Dermatovenereology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Staré Město, Czech Republic.

PMID: 39912554
DOI: 10.1111/jdv.20581

Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study

Tiago Torres et al. J Eur Acad Dermatol Venereol. 2025 Sep.

. 2025 Sep;39(9):e756-e761.

doi: 10.1111/jdv.20581. Epub 2025 Feb 6.

Authors

Affiliations

¹ Department of Dermatology, Centro Hospitalar Universitário de Santo António Porto, Porto, Portugal.
² Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
³ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁴ Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada.
⁵ Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
⁶ Probity Medical Research, Toronto, Ontario, Canada.
⁷ Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
⁸ Dermatology Research Institute, Calgary, Alberta, Canada.
⁹ Skin Health & Wellness Centre, Calgary, Alberta, Canada.
¹⁰ Probity Medical Research, Calgary, Alberta, Canada.
¹¹ Department of Medical Sciences, Dermatology Clinic, University of Turin, Turin, Italy.
¹² Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy.
¹³ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
¹⁴ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
¹⁵ Department of Dermatology, Unidade Local de Saúde de São João, Porto, Portugal.
¹⁶ Faculty of Medicine, University of Porto, Porto, Portugal.
¹⁷ Dermatology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
¹⁸ Department of Dermatology-Venereology, Aristotle University School of Medicine, Thessaloniki, Greece.
¹⁹ Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
²⁰ Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
²¹ Department of Health Sciences Dermatology Section, University of Florence, Florence, Italy.
²² Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
²³ U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
²⁴ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
²⁵ Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland.
²⁶ Department of Dermatovenereology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Staré Město, Czech Republic.

PMID: 39912554
DOI: 10.1111/jdv.20581

No abstract available

PubMed Disclaimer

References

REFERENCES

1. Schuler CF 4th, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2023;151(5):1145–1154.
1. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–40.
1. van den Reek JMPA, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, et al. Drug survival studies in dermatology:principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5.
1. Pezzolo E, Ortoncelli M, Ferrucci SM, Guanti MB, Schena D, Napolitano M, et al. Drug survival of Upadacitinib and predicting factors of discontinuation in adult patients affected by moderate‐to‐severe atopic dermatitis: an Italian multicenter analysis. J Clin Med. 2024;13(2):553.
1. Pezzolo E, Schena D, Gambardella A, Rossi M, Barei F, Calzavara Pinton P, et al. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate‐to‐severe atopic dermatitis in adults: a multicentre real‐world study. J Eur Acad Dermatol Venereol. 2024;38(1):e11–e13.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study

Affiliations

Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study

Authors

Affiliations

References

REFERENCES

Publication types

LinkOut - more resources

Full Text Sources